Ilyang Pharmaceutical (007570) Fundamentals 2026 — P/E 6.7x, Revenue Analysis | SniperIQ
Ilyang Pharmaceutical (007570) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩140.9B, trading at ₩7860.00 on the KSC. This SniperIQ fundamentals page covers Ilyang Pharmaceutical's valuation (P/E 6.7x, P/B 0.5x), profitability (net margin 7.3%), revenue (₩272.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ilyang Pharmaceutical's market cap?
Ilyang Pharmaceutical (007570) has a market capitalization of approximately ₩140.9B, trading at ₩7860.00 on the KSC. Market cap moves with the live share price.
What is Ilyang Pharmaceutical's P/E ratio?
Ilyang Pharmaceutical's trailing twelve-month P/E ratio is 6.7x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ilyang Pharmaceutical?
Ilyang Pharmaceutical runs a net profit margin of 7.3%, a gross margin of 40.7%, and an operating margin of -2.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ilyang Pharmaceutical generate?
Ilyang Pharmaceutical reported revenue of ₩272.2B for fiscal year 2025, with net income of ₩6.9B and earnings per share (EPS) of 375.42. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ilyang Pharmaceutical pay a dividend?
Ilyang Pharmaceutical offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ilyang Pharmaceutical financially healthy?
Ilyang Pharmaceutical carries a debt-to-equity ratio of 0.44x and a current ratio of 0.96x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ilyang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ilyang Pharmaceutical (007570) the key facts are: market cap ₩140.9B, P/E 6.7x, revenue ₩272.2B, 52-week range 7290-16240. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ilyang Pharmaceutical's full fundamentals live
Get Ilyang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.